Embodiments described herein are directed to employing an aggregation of participant sensor coverage areas to determine if there are missing coverage areas or unwanted overlapping coverage areas. If there are missing coverage areas, then at least one participant is instructed to modify its sensor coverage area to at least partially cover the missing coverage area. Conversely, if at least one participant has a sensor that is providing unwanted overlap of other sensor coverage areas, then that participant may be instructed to stop using that sensor, utilize that sensor for other data transmission purposes, or modify the coverage area to be non- or less-overlapping.

Embodiments described herein are directed to employing an aggregation of participant sensor coverage areas to determine if there are missing coverage areas or unwanted overlapping coverage areas. If there are missing coverage areas, then at least one participant is instructed to modify its sensor coverage area to at least partially cover the missing coverage area. Conversely, if at least one participant has a sensor that is providing unwanted overlap of other sensor coverage areas, then that participant may be instructed to stop using that sensor, utilize that sensor for other data transmission purposes, or modify the coverage area to be non- or less-overlapping.

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.

##STR00001##

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.

##STR00001##

The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.

##STR00001##

The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.

##STR00001##

Salts and solid state forms of Valbenazine, including Valbenazine ditosylate, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof are disclosed.

Salts and solid state forms of Valbenazine, including Valbenazine ditosylate, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof are disclosed.

Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.

The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.

##STR00001##